Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.
You may also be interested in...
Daiichi Sankyo Gains U.S. Diabetes Indication For Cholesterol Drug WelChol
Daiichi Sankyo received U.S. FDA sNDA approval for its cholesterol drug WelChol (colesevelam) as an adjunct therapy to improve glycemic control in patients with type 2 diabetes Jan. 18
Daiichi Sankyo Gains Diabetes Indication For Cholesterol Drug WelChol
Therapy indicated as adjunctive treatment to improve glycemic control in type 2 diabetes patients.
Daiichi Sankyo Gains Diabetes Indication For Cholesterol Drug WelChol
Therapy indicated as adjunctive treatment to improve glycemic control in type 2 diabetes patients.